Positive News Sentiment NASDAQ:ACXP Acurx Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Acurx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $3.75 -0.04 (-1.06%) (As of 07/1/2022 12:00 AM ET) Add Compare Share Today's Range$3.63▼$3.8250-Day Range$2.42▼$4.0052-Week Range$2.33▼$6.35Volume10,508 shsAverage Volume22,854 shsMarket Capitalization$38.49 millionP/E RatioN/ADividend YieldN/APrice Target$12.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Acurx Pharmaceuticals Stock Forecast (MarketRank)Analyst RatingBuy3.00 Rating ScoreUpside/Downside220.0% Upside$12.00 Price TargetShort InterestHealthy0.55% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.70 out of 5 starsMedical Sector843rd out of 1,428 stocksPharmaceutical Preparations Industry421st out of 682 stocks 3.5 Analyst's Opinion Consensus RatingAcurx Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.00, Acurx Pharmaceuticals has a forecasted upside of 220.0% from its current price of $3.75.Amount of Analyst CoverageAcurx Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.55% of the outstanding shares of Acurx Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverAcurx Pharmaceuticals has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Acurx Pharmaceuticals has recently increased by 16.26%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAcurx Pharmaceuticals does not currently pay a dividend.Dividend GrowthAcurx Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACXP. Previous Next 3.3 News and Social Media Coverage News SentimentAcurx Pharmaceuticals has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Acurx Pharmaceuticals this week, compared to 0 articles on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Acurx Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 0.72% of the stock of Acurx Pharmaceuticals is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Acurx Pharmaceuticals is -2.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Acurx Pharmaceuticals is -2.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAcurx Pharmaceuticals has a P/B Ratio of 3.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ACXP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acurx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address About Acurx PharmaceuticalsAcurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.Read More ACXP Stock News HeadlinesMay 11, 2022 | investing.comAcurx Pharmaceuticals Tops Q1 EPS by 7cMay 11, 2022 | seekingalpha.comAcurx Pharmaceuticals GAAP EPS of -$0.26 beats by $0.07July 2, 2022 | Investing Daily (Ad)Former Lawyer Went From $50K To $5.3M Trading OptionsSlaving away for 70 hrs a week as a lawyer in Chicago, I was miserable. I ran into guys who worked the trading floor at the local exchange. I began trading the same way they did. I started out with $50K (much more than I needed, actually). I grew my $50K into $5.3M May 11, 2022 | finance.yahoo.comAcurx Pharmaceuticals, Inc. Reports First Quarter 2022 Results and Provides Business UpdateApril 29, 2022 | finance.yahoo.comAcurx Pharmaceuticals, Inc. to Discuss 2022 First Quarter Financial Results on May 11, 2022 Conference Call and Provide Business UpdateMarch 29, 2022 | marketwatch.comAcurx Pharmaceuticals Stands As Front-Line CDI Treatment Contender After Pfizer Misses Primary Endpoint In CDI Drug Trial (NASDAQ: ACXP)March 24, 2022 | finance.yahoo.comAcurx Pharmaceuticals (NASDAQ:ACXP) Is In A Good Position To Deliver On Growth PlansMarch 17, 2022 | seekingalpha.comAcurx Pharmaceuticals GAAP EPS of -$1.49 beats by $0.20July 2, 2022 | Investing Daily (Ad)Former Lawyer Went From $50K To $5.3M Trading OptionsSlaving away for 70 hrs a week as a lawyer in Chicago, I was miserable. I ran into guys who worked the trading floor at the local exchange. I began trading the same way they did. I started out with $50K (much more than I needed, actually). I grew my $50K into $5.3M March 17, 2022 | finance.yahoo.comAcurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2021 Results and Provides Business UpdateMarch 16, 2022 | finance.yahoo.comAcurx Pharmaceuticals to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28-30, 2022 from 9:00 a.m. - 5:00 p.m. EDTFebruary 7, 2022 | finance.yahoo.comAcurx Announces Publication of Positive Phase 2a Clinical Trial Results of Ibezapolstat for CDI in Clinical Infectious DiseasesNovember 30, 2021 | benzinga.comAcurx Pharmaceuticals Earns $12 Price Target From Maxim Group; Ibezapolstat Stays In Focus To Treat C. difficile (NASDAQ: ACXP)November 12, 2021 | markets.businessinsider.comAcurx Pharmaceuticals, Inc. Reports Third Quarter 2021 Results and Provides Business UpdateNovember 10, 2021 | benzinga.comAcurx Pharmaceuticals' Drug Candidate Ibezapolstat Continues To Score Clinical Wins In Treating C. Difficile (NASDAQ: ACXP)October 27, 2021 | finance.yahoo.comAcurx Pharmaceuticals to Discuss 2021 Third Quarter Financial Results on November 15, 2021 Conference Call and Provide Business UpdateOctober 4, 2021 | finance.yahoo.comAcurx Presents Positive Ibezapolstat Microbiome Data from Its Phase 2a Trial at IDWeekSeptember 29, 2021 | finance.yahoo.comAcurx Pharmaceuticals to Participate in the A.G.P. Biotech and Specialty Pharma Conference October 13, 2021September 27, 2021 | finance.yahoo.comAcurx Announces New Microbiome Data from Its Phase 2a Clinical Trial of Ibezapolstat for CDI in a Scientific Poster Presentation at IDWeek 2021 ConferenceSeptember 25, 2021 | finance.yahoo.comWe Think Acurx Pharmaceuticals (NASDAQ:ACXP) Can Easily Afford To Drive Business GrowthSeptember 21, 2021 | benzinga.comVIDEO Report: Acurx Pharmaceuticals' Ibezapolstat In Focus As A Best-In-Class Treatment For Gram Positive Infections (NASDAQ: ACXP)September 13, 2021 | finance.yahoo.comCEO Spotlight: Acurx Pharmaceuticals in Focus with CEO David Luci Talking Potentially Transformative Phase 2b Trial, Pipeline, and Potential Near-Term CatalystsSeptember 2, 2021 | finance.yahoo.comAcurx Pharmaceuticals to Join the Russell Microcap Index®August 31, 2021 | finance.yahoo.comAcurx Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021August 25, 2021 | benzinga.comAcurx Pharmaceuticals Plan To Change The Antibiotics Landscape Is Simple- Make Better Drugs That Target Gram-Positive InfectionsAugust 17, 2021 | finance.yahoo.comCEO Presenting on the Emerging Growth Conference on August 18. Register NowAugust 16, 2021 | finance.yahoo.comAcurx Pharmaceuticals, Inc. Reports Second Quarter 2021 Results and Provides Business UpdateSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ACXP CUSIPN/A CIK1736243 Webwww.acurxpharma.com Phone917-533-1469FaxN/AEmployees3Year FoundedN/ACompany Calendar Last Earnings5/10/2022Today7/02/2022Next Earnings (Estimated)8/15/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$12.00 High Stock Price Forecast$12.00 Low Stock Price Forecast$12.00 Forecasted Upside/Downside+220.0%Consensus RatingBuy Rating Score (0-4)3 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12.75 million Net MarginsN/A Pretax MarginN/A Return on Equity-105.43% Return on Assets-97.83% Debt Debt-to-Equity RatioN/A Current Ratio17.89 Quick Ratio17.89 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.23 per share Price / Book3.05Miscellaneous Outstanding Shares10,263,000Free FloatN/AMarket Cap$38.49 million OptionableNot Optionable BetaN/A Acurx Pharmaceuticals Frequently Asked Questions Should I buy or sell Acurx Pharmaceuticals stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Acurx Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Acurx Pharmaceuticals stock. View analyst ratings for Acurx Pharmaceuticals or view top-rated stocks. What is Acurx Pharmaceuticals' stock price forecast for 2022? 1 brokerages have issued 12-month price targets for Acurx Pharmaceuticals' shares. Their ACXP stock forecasts range from $12.00 to $12.00. On average, they anticipate Acurx Pharmaceuticals' share price to reach $12.00 in the next year. This suggests a possible upside of 220.0% from the stock's current price. View analysts' price targets for Acurx Pharmaceuticals or view top-rated stocks among Wall Street analysts. How has Acurx Pharmaceuticals' stock performed in 2022? Acurx Pharmaceuticals' stock was trading at $4.3214 at the start of the year. Since then, ACXP stock has decreased by 13.2% and is now trading at $3.75. View the best growth stocks for 2022 here. When is Acurx Pharmaceuticals' next earnings date? Acurx Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022. View our earnings forecast for Acurx Pharmaceuticals. How were Acurx Pharmaceuticals' earnings last quarter? Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) posted its quarterly earnings results on Tuesday, May, 10th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.07. View Acurx Pharmaceuticals' earnings history. Who are Acurx Pharmaceuticals' key executives? Acurx Pharmaceuticals' management team includes the following people: Mr. Robert J. DeLuccia, Co-Founder & Exec. Chairman (Age 76, Pay $464.77k) (LinkedIn Profile)Mr. David P. Luci CPA, CPA, Esq., J.D., Corp. Sec., Co-Founder, Pres, CEO & Director (Age 55, Pay $443.14k) (LinkedIn Profile)Mr. Robert G. Shawah CPA, Co-Founder & CFO (Age 55, Pay $200.34k) Who are some of Acurx Pharmaceuticals' key competitors? Some companies that are related to Acurx Pharmaceuticals include Nuvectis Pharma (NVCT), Avadel Pharmaceuticals (AVDL), Annexon (ANNX), CorMedix (CRMD), CorMedix (CRMD), Pieris Pharmaceuticals (PIRS), TFF Pharmaceuticals (TFFP), Silverback Therapeutics (SBTX), Assertio (ASRT), Rain Therapeutics (RAIN), Spectrum Pharmaceuticals (SPPI), Viracta Therapeutics (VIRX), ObsEva (OBSV), Satsuma Pharmaceuticals (STSA) and F-star Therapeutics (FSTX). View all of ACXP's competitors. When did Acurx Pharmaceuticals IPO? (ACXP) raised $15 million in an initial public offering on Friday, June 25th 2021. The company issued 2,500,000 shares at $5.00-$7.00 per share. Alexander Capital, L.P. and Network 1 Financial Securities acted as the underwriters for the IPO. What is Acurx Pharmaceuticals' stock symbol? Acurx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACXP." How do I buy shares of Acurx Pharmaceuticals? Shares of ACXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Acurx Pharmaceuticals' stock price today? One share of ACXP stock can currently be purchased for approximately $3.75. How much money does Acurx Pharmaceuticals make? Acurx Pharmaceuticals (NASDAQ:ACXP) has a market capitalization of $38.49 million. The company earns $-12.75 million in net income (profit) each year or ($1.52) on an earnings per share basis. How many employees does Acurx Pharmaceuticals have? Acurx Pharmaceuticals employs 3 workers across the globe. How can I contact Acurx Pharmaceuticals? The official website for Acurx Pharmaceuticals is www.acurxpharma.com. The company can be reached via phone at 917-533-1469 or via email at davidluci@acurxpharma.com. This page (NASDAQ:ACXP) was last updated on 7/2/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
